A bill for an act relating to direct acting antiviral medications, including prior authorization requirements, and the Iowa medical assistance drug utilization review commission.

This bill (SF 433) removes a prior authorization requirement for direct-acting antiviral medications treating hepatitis C that are already on Iowa's preferred drug list for Medicaid. It directly affects Medicaid patients seeking hepatitis C treatment by simplifying access to these specific medications. The bill also requires the Iowa Medical Assistance Drug Utilization Review Commission to review the drug Vosevi for potential inclusion on the preferred formulary by July 1, 2026, per federal guidelines.